EMMAUS LIFE SCIENCES, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.5M | $16.7M | $29.6M | $18.4M | $20.6M | $23.2M | $22.8M | $16.5M |
| Cost of Revenue | $857.0K | $1.2M | $1.3M | $2.6M | $3.3M | $2.2M | $1.1M | $993.0K |
| Gross Profit | $11.6M | $15.5M | $28.3M | $15.8M | $17.3M | $20.9M | $21.7M | $15.5M |
| Gross Margin | 93.1% | 92.8% | 95.5% | 85.9% | 83.9% | 90.3% | 95.2% | 94.0% |
| Operating Expenses | ||||||||
| Research & Development | $313.0K | $657.0K | $1.2M | $1.7M | $4.1M | $2.4M | $2.2M | $1.7M |
| SG&A Expense | $8.2M | $10.7M | $14.9M | $13.2M | $13.4M | $13.7M | $17.0M | $17.5M |
| Operating Income | $231.0K | $-1.9M | $3.5M | $-6.6M | $-6.1M | $-32.0K | $-4.5M | $-8.5M |
| Operating Margin | 1.9% | -11.4% | 12.0% | -35.8% | -29.7% | -0.1% | -19.8% | -51.4% |
| Interest Expense | $7.1M | $5.5M | $7.4M | $5.0M | $3.1M | $6.0M | $27.6M | $22.8M |
| Pretax Income | $-7.5M | $-6.4M | $-3.8M | $-10.6M | $-15.9M | $973.0K | $-54.7M | $-72.5M |
| Income Tax Expense | $9.0K | $29.0K | $-59.0K | $60.0K | $25.0K | $-381.0K | $164.0K | $39.0K |
| Net Income | $-7.5M | $-6.5M | $-3.7M | $-10.6M | $-15.9M | $1.4M | $-54.8M | $-72.6M |
| Net Margin | -60.2% | -38.7% | -12.6% | -57.8% | -77.4% | 5.8% | -241.0% | -441.0% |
| EPS (Basic) | $-0.12 | $-0.10 | $-0.07 | $-0.21 | $-0.32 | $30.00 | $-1.30 | $-1.97 |
| EPS (Diluted) | $-0.12 | $-0.10 | $-0.07 | $-0.21 | $-0.32 | $30.00 | $-1.30 | $-1.97 |
| Shares Outstanding (Basic) | 64.0M | 63.2M | 53.1M | 49.4M | 49.3M | 48.9M | 42.3M | 36.9M |
| Shares Outstanding (Diluted) | 64.0M | 63.2M | 53.1M | 49.4M | 49.3M | 48.9M | 42.3M | 36.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |